Literature DB >> 20378168

High frequency of immature cells at diagnosis predicts high minimal residual disease level in childhood acute lymphoblastic leukemia.

Martin Ebinger1, Kai-Erik Witte, Jörg Ahlers, Iris Schäfer, Maya André, Gunter Kerst, Hans-Gerhard Scheel-Walter, Peter Lang, Rupert Handgretinger.   

Abstract

Prognosis for children with acute lymphoblastic leukemia (ALL) has considerably improved, yet relapse still occurs in a significant proportion of patients. Conceivably, the most immature leukemia cells may be more resistant to therapy and initiate relapse. We studied 42 patients with childhood ALL treated according to the ALL-BFM 2000 protocol. At diagnosis, we determined the characteristic immunophenotype of the leukemic cells by flow cytometry and also investigated the expression of CD34 and CD38 to define a population of immunophenotypically immature cells (CD34(+)/CD38(-)). We then studied levels of minimal residual disease (MRD) after induction therapy (day 33) and after consolidation therapy (week 12). We found a significant, increasing correlation between the prevalence of CD34(+)/CD38(-) cells at diagnosis and MRD levels at day 33 and week 12. Our results suggest that the initial frequency of CD34(+)/CD38(-) cells may serve as a prognostic marker in pediatric ALL. Copyright 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20378168     DOI: 10.1016/j.leukres.2010.03.023

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  10 in total

1.  KLF4 translation level is associated with differentiation stage of different pediatric leukemias in both cell lines and primary samples.

Authors:  Xiaoping Guo; Yongmin Tang
Journal:  Clin Exp Med       Date:  2012-05-17       Impact factor: 3.984

2.  Cluster of differentiation 96 as a leukemia stem cell-specific marker and a factor for prognosis evaluation in leukemia.

Authors:  Wen DU; Yanjie Hu; Cong Lu; Juan Li; Wei Liu; Yanli He; Ping Wang; Chen Cheng; Y U Hu; Shiang Huang; Junxia Yao; Jin'e Zheng
Journal:  Mol Clin Oncol       Date:  2015-04-24

3.  High levels of CD34+CD38low/-CD123+ blasts are predictive of an adverse outcome in acute myeloid leukemia: a Groupe Ouest-Est des Leucemies Aigues et Maladies du Sang (GOELAMS) study.

Authors:  François Vergez; Alexa S Green; Jerome Tamburini; Jean-Emmanuel Sarry; Baptiste Gaillard; Pascale Cornillet-Lefebvre; Melanie Pannetier; Aymeric Neyret; Nicolas Chapuis; Norbert Ifrah; François Dreyfus; Stéphane Manenti; Cecile Demur; Eric Delabesse; Catherine Lacombe; Patrick Mayeux; Didier Bouscary; Christian Recher; Valerie Bardet
Journal:  Haematologica       Date:  2011-09-20       Impact factor: 9.941

4.  Minimal Residual Disease in AML: Why Has It Lagged Behind Pediatric ALL?

Authors:  Elisabeth Paietta
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2015-06

5.  Leukemia Stem Cell Frequency at Diagnosis Correlates With Measurable/Minimal Residual Disease and Impacts Survival in Adult Acute Myeloid Leukemia.

Authors:  Azza M Kamel; Nahla M Elsharkawy; Eman Z Kandeel; Marwa Hanafi; Mohammed Samra; Randa A Osman
Journal:  Front Oncol       Date:  2022-04-08       Impact factor: 5.738

6.  Antiproliferative and Apoptosis-Inducing Activities of Thymoquinone in Lymphoblastic Leukemia Cell Line.

Authors:  Amin Soltani; Batoul Pourgheysari; Hedayatollah Shirzad; Zahra Sourani
Journal:  Indian J Hematol Blood Transfus       Date:  2016-12-08       Impact factor: 0.900

Review 7.  Targeting CD38 in Neoplasms and Non-Cancer Diseases.

Authors:  Wojciech Szlasa; Jakub Czarny; Natalia Sauer; Katarzyna Rakoczy; Natalia Szymańska; Jakub Stecko; Maksymilian Kołodziej; Maciej Kaźmierczak; Ewa Barg
Journal:  Cancers (Basel)       Date:  2022-08-28       Impact factor: 6.575

8.  Interest in Determining the CD34+ CD38- Phenotype in the Diagnosis and Prognosis of Acute Leukemia in Abidjan - Côte d'Ivoire.

Authors:  Duni Sawadogo; Aissata Tolo; Hermance Kassi; Mahawa Sangare; Andre Inwoley
Journal:  Mediterr J Hematol Infect Dis       Date:  2013-04-10       Impact factor: 2.576

9.  Targeting EpCAM (CD326) for immunotherapy in hepatoblastoma.

Authors:  Sorin Armeanu-Ebinger; Alexander Hoh; Julia Wenz; Joerg Fuchs
Journal:  Oncoimmunology       Date:  2013-01-01       Impact factor: 8.110

10.  Alantolactone selectively ablates acute myeloid leukemia stem and progenitor cells.

Authors:  Yahui Ding; Huier Gao; Yu Zhang; Ye Li; Neil Vasdev; Yingdai Gao; Yue Chen; Quan Zhang
Journal:  J Hematol Oncol       Date:  2016-09-22       Impact factor: 17.388

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.